用于慢性HBV感染治疗的检查点抑制剂和治疗性疫苗。

StephenW

Front Immunol. 2020 Mar 4;11:401. doi: 10.3389/fimmu.2020.00401. eCollection 2020.
Checkpoint Inhibitors and Therapeutic Vaccines for the Treatment of Chronic HBV Infection.
Hoogeveen RC1, Boonstra A1.
Author information

1
    Division of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, Netherlands.

Abstract

Treatment of chronic hepatitis B virus (HBV) infection is highly effective in suppressing viral replication, but complete cure is rarely achieved. In recent years, substantial progress has been made in the development of immunotherapy to treat cancer. Applying these therapies to improve the management of chronic HBV infection is now being attempted, and has become an area of active research. Immunotherapy with vaccines and checkpoint inhibitors can boost T cell functions in vitro, and therefore may be used to reinvigorate the impaired HBV-specific T cell response. However, whether these approaches will suffice and restore antiviral T cell immunity to induce long-term HBV control remains an open question. Recent efforts have begun to describe the phenotype and function of HBV-specific T cells on the single epitope level. An improved understanding of differing T cell specificities and their contribution to HBV control will be instrumental for advancement of the field. In this review, we outline correlates of successful versus inadequate T cell responses to HBV, and discuss the rationale behind therapeutic vaccines and checkpoint inhibitors for the treatment of chronic HBV infection.

Copyright © 2020 Hoogeveen and Boonstra.
KEYWORDS:

HBV-specific T cells; checkpoint inhibitors; hepatitis B virus; immunotherapy; therapeutic vaccines

PMID:
    32194573
PMCID:
    PMC7064714
DOI:
    10.3389/fimmu.2020.00401

StephenW

前免疫。 2020年3月4日； 11：401。Doi：10.3389 / fimmu.2020.00401。 ECollection 2020。
用于慢性HBV感染治疗的检查点抑制剂和治疗性疫苗。
Hoogeveen RC1，Boonstra A1。
作者信息

1个
荷兰鹿特丹大学医学中心，伊拉斯姆斯大学胃肠病和肝病科。

抽象

慢性乙型肝炎病毒（HBV）感染的治疗在抑制病毒复制方面非常有效，但很少能完全治愈。近年来，在开发用于治疗癌症的免疫疗法方面已取得实质性进展。目前正在尝试使用这些疗法来改善慢性HBV感染的管理，并已成为活跃的研究领域。疫苗和检查点抑制剂的免疫疗法可在体外增强T细胞功能，因此可用于恢复受损的HBV特异性T细胞反应。但是，这些方法是否足以满足并恢复抗病毒T细胞免疫以诱导长期HBV控制仍是一个悬而未决的问题。最近的努力已开始在单个表位水平上描述HBV特异性T细胞的表型和功能。更好地了解不同的T细胞特异性及其对HBV控制的贡献将有助于该领域的发展。在这篇综述中，我们概述了成功和不充分的T细胞对HBV反应的相关性，并讨论了用于治疗慢性HBV感染的治疗性疫苗和检查点抑制剂的基本原理。

版权所有©2020 Hoogeveen和Boonstra。
关键字：

HBV特异性T细胞；检查点抑制剂；乙型肝炎病毒；免疫疗法治疗性疫苗

PMID：
32194573
PMCID：
PMC7064714
DOI：
10.3389 / fimmu.2020.00401

StephenW

https://www.frontiersin.org/articles/10.3389/fimmu.2020.00401/pdf